Immune Therapeutics, Inc. Contracts & Agreements

First Amendment to Promissory Note between Immune Therapeutics, Inc. and Ira Gaines dated November 4, 2022 (Filed With SEC on April 16, 2024)

Settlement Agreement between Immune Therapeutics, Inc. and Jack Brewer dated October 23, 2022 (Filed With SEC on April 16, 2024)

Executive Consulting Agreement, dated July 25, 2023, between Immune Therapeutics, Inc. and Noreen Griffin (Filed With SEC on September 13, 2023)

Amendment No. 1 to Executive Consulting Agreement between the Company and Kelly O. Wilson dated April 12, 2023 (Filed With SEC on April 20, 2023)

Settlement Agreement between the Company and Statera Biopharma, Inc. dated April 12, 2023 (Filed With SEC on April 20, 2023)

Amendment No. 3 to License Agreement between the Company and Statera Biopharma, Inc. dated April 15, 2023 (Filed With SEC on April 20, 2023)

First Amendment to Promissory Note between Immune Therapeutics, Inc. and Ira Gaines dated November 4, 2022 (Filed With SEC on April 10, 2023)

Settlement Agreement between Immune Therapeutics, Inc. and Jack Brewer dated October 23, 2022 (Filed With SEC on April 10, 2023)

Consulting Agreement, dated November 1, 2022, between Immune Therapeutics, Inc. and Kelly O. Wilson (Filed With SEC on November 9, 2022)

Consulting Agreement, dated November 1, 2022, between Immune Therapeutics, Inc. and Glen Farmer (Filed With SEC on November 9, 2022)

Intellectual Property License Agreement, dated September 30, 2022, between Immune Therapeutics, Inc. and TaiwainJ Pharmaceuticals Co. Ltd (Filed With SEC on October 12, 2022)

Convertible Promissory Note in the Principal Amount of $100,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps (Filed With SEC on July 22, 2022)

Convertible Promissory Note in the Principal Amount of $200,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps (Filed With SEC on July 22, 2022)

Separation and Release Agreement, dated July 19, 2022, between Kevin Phelps and Immune Therapeutics, Inc (Filed With SEC on July 22, 2022)

Term Sheet (Filed With SEC on July 7, 2022)

Note Purchase Agreement dated November 10, 2020 entered into by Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on March 18, 2022)

Note Assignment dated November 10, 2020 between Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on March 18, 2022)

Note Exchange Agreement dated March 31, 2021 between Immune Therapeutics, Inc. and Global Reverb Corporation and Robert J. Dailey (Filed With SEC on March 18, 2022)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Global Reverb Corporation (Filed With SEC on March 18, 2022)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Robert J. Dailey (Filed With SEC on March 18, 2022)

[REVISED CYTOCOM AGREEMENT] (Filed With SEC on August 16, 2021)

Letter of Intent, dated May 25, 2021 (Filed With SEC on June 2, 2021)

Note Purchase Agreement dated November 10, 2020 entered into by Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on May 24, 2021)

Note Assignment dated November 10, 2020 between Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on May 24, 2021)

Note Exchange Agreement dated March 31, 2021 between Immune Therapeutics, Inc. and Global Reverb Corporation and Robert J. Dailey (Filed With SEC on May 24, 2021)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Global Reverb Corporation (Filed With SEC on May 24, 2021)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Robert J. Dailey (Filed With SEC on May 24, 2021)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on April 15, 2021)

Agreement dated August 12, 2020 between Immune Therapeutics, Inc. and Cytocom, Inc. assigning all of .Immune Therapeutics right, title and interest in LDN and MENK in Developing... (Filed With SEC on November 16, 2020)

Amendment to the Articles of Incorporation filed February 5, 2020 approving a reverse split of issued and outstanding shares of common stock by 1,000 to 1 (Filed With SEC on August 14, 2020)

Amendment to the Articles of Incorporation filed March 12, 2020 approving an increase in authorized shares of common stock from 500,000,000 to 750,000,000 (Filed With SEC on August 14, 2020)

Short-form Executive Employment Agreement dated July 22, 2020 (Filed With SEC on July 27, 2020)

Board Resolution dated July 24, 2020 (Filed With SEC on July 27, 2020)

Securities Purchase Agreement dated as of May 4, 2020 with Geneva Roth Remark Holdings, Inc, together with Exhibit A Convertible Promissory Note in the principal amount of $53,000 (Filed With SEC on June 29, 2020)

Securities Purchase Agreement dated as of June 15, 2020 with Geneva Roth Remark Holdings, Inc, together with Exhibit A Convertible Promissory Note in the principal amount of... (Filed With SEC on June 29, 2020)

Amendment to Articles of Incorporation filed with the State of Florida on February 6, 2020, together with the Corporate Resolution of the Board of Directors dated February 2, 2020... (Filed With SEC on June 29, 2020)

Amendment to Articles of Incorporation filed with the State of Florida on March 12, 2020, 2020 (Filed With SEC on June 29, 2020)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on May 14, 2020)

Second Amendment to License Agreement with Cytocom Inc., effective December 31, 2018 and signed April 8, 2019 (Filed With SEC on May 14, 2020)

License Agreement dated January 15, 2020 with Forte Biotechnology Intl. Corp (Filed With SEC on May 14, 2020)

Convertible Promissory Note dated March 30, 2020 to Redstart Holdings Corp. in the principal amount of $53,000 (Filed With SEC on May 14, 2020)

PRC Amendment to The Second Amendment to the License Agreement effective December 31, 2018 with Cytocom, Inc. and signed May 12, 2020 (Filed With SEC on May 14, 2020)

Mutual Release and Non-Disparagement Agreement effective April 30, 2020 (Filed With SEC on May 5, 2020)

Board Resolution dated April 30, 2020 (Filed With SEC on May 5, 2020)

Letter of Intent dated March 17, 2020 (Filed With SEC on March 20, 2020)

Board Resolution (Filed With SEC on February 19, 2020)

Employment Agreement with Michael Handley (Filed With SEC on September 25, 2019)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on May 20, 2019)

Second Amendment to License Agreement by and between: Cytocom Inc. and Immune Therapeutics Inc., signed April 8, 2019 (Filed With SEC on May 20, 2019)

Letter to Shareholders (Filed With SEC on May 15, 2019)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on April 16, 2019)

Restated Agreement (Filed With SEC on June 11, 2018)

Stock Agreement (Filed With SEC on June 11, 2018)

Loan agreement and promissory note with Joel Yanowitz, dated January 9, 2018, for $50,000 (Filed With SEC on May 15, 2018)

Loan agreement and promissory note with Rogoff Family Trust, dated February 13, 2018, for $50,000 (Filed With SEC on May 15, 2018)

Promissory Note Settlement Agreement, dated September 26, 2014, between Immune Therapeutics, Inc. and Robert Dailey for notes equaling $399,000 (Filed With SEC on April 2, 2018)

Promissory Note Settlement Agreement, dated September 26, 2014, between Immune Therapeutics, Inc. and Robert Dailey for notes equaling $400,000 (Filed With SEC on April 2, 2018)

Services Agreement, dated December 15, 2014, between Immune Therapeutics, Inc. and Aronstam Management Services, Inc (Filed With SEC on April 2, 2018)

Real Property Leases for Florida Office and Extensions dated July 19, 2017 and November 13, 2017 (Filed With SEC on April 2, 2018)

Extension of Employment Agreement with Noreen Griffin dated March 9, 2018 (Filed With SEC on April 2, 2018)

Extension of AHAR Agreement dated March 29, 2016 (Filed With SEC on April 2, 2018)

Extension of Employment Agreement with Peter Aronstam dated July 1, 2017 (Filed With SEC on April 2, 2018)

Consulting Agreement with Joyce Banda dated September 1, 2016 (Filed With SEC on April 2, 2018)

Intellectual Property Assignment Agreement with Cytocom, Inc. dated September 4, 2015 (Filed With SEC on April 2, 2018)

Consulting Master Services Agreement with Cot Orphan, LLC dated February 16, 2016 (Filed With SEC on April 2, 2018)

Securities Purchase Agreement and related agreements with JMJ Financial dated April 12, 2016 (filed as Exhibit 10.1 to our Current Report 8-K on April 18, 2016, and incorporated... (Filed With SEC on April 2, 2018)

Patent License Agreement dated September 24, 2014 between Dr. Jill P. Smith, LDN Research Group LLC and Cytocom, Inc. and related agreements (Filed With SEC on April 2, 2018)

Promissory Note dated February 6, 2017 issued to Phoenix Fund Management, LLC (Filed With SEC on April 2, 2018)

Settlement agreement with Phoenix Fund Management, LLC dated February 28, 2017 (Filed With SEC on April 2, 2018)

Settlement agreement with Mr. Marshall Faulk dated April 3, 2017 (Filed With SEC on April 2, 2018)

Promissory Note dated April 5, 2017 to Robert J. Dailey in the principal amount of $150,000 (Filed With SEC on April 2, 2018)

Securities Purchase Agreement and Warrant dated May 1, 2017 with Ira Gaines (Filed With SEC on April 2, 2018)

Distribution Agreement with TNI BioTech International Ltd. and Omaera Pharmaceuticals Ltd. Dated August 22, 2017 (Filed With SEC on April 2, 2018)

Settlement and mutual release agreement dated October 12, 2017 with Phoenix Fund Management, LLC and Far East Holdings, LLC (Filed With SEC on April 2, 2018)

Securities Purchase Agreement dated October 25, 2017 with Iliad Research and Trading, L.P (Filed With SEC on April 2, 2018)

Iliad Research and Trading (i) promissory note and (ii) warrant dated October 25, 2017 (Filed With SEC on April 2, 2018)

Independent Corporate Development and Consulting Agreement with CSJ Group, LLC, and Advanced BioStrategies, Inc. dated December 5, 2017 (Filed With SEC on April 2, 2018)

Independent Corporate Development and Legal Advising Agreement with CSJ and August Strategic & Legal Advisors, Inc. dated December 6, 2017 (Filed With SEC on April 2, 2018)

Securities Purchase Agreement and Note with Iliad Research & Trading LP dated October 20, 2017 (Filed With SEC on November 14, 2017)

Settlement and Mutual Release Agreement with Phoenix Fund Management, LLC dated October 12, 2017 (Filed With SEC on November 14, 2017)

Distribution Agreement with Omaera Pharmaceuticals Ltd. dated August 22, 2017 (Filed With SEC on November 14, 2017)

ADDENDUMTO COMMONSTOCK PURCHASE WARRANT DOCUMENTW-04122016 (Filed With SEC on December 1, 2016)

CONTRACTFOR THE MANUFACTURING OF PHARMACEUTICAL PRODUCTS (Filed With SEC on November 15, 2016)

EXCLUSIVEAGENCY AGREEMENT (Filed With SEC on November 15, 2016)

ADDENDUMTO COMMONSTOCK PURCHASE WARRANT DOCUMENTW-04122016 (Filed With SEC on November 10, 2016)

EMPLOYMENTAGREEMENT (Filed With SEC on August 15, 2016)

CONTRACTFOR THE COMPOUNDING OF PHARMACEUTICAL PRODUCTS (Filed With SEC on May 20, 2016)

LODONAL" IN THE TREATMENT OF SUBJECTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) A Bridging Study to Evaluate the Effects of LODONAL" as an Immune-System Regulating Agent in Subjects... (Filed With SEC on December 4, 2015)

ROYALTY AGREEMENT (Filed With SEC on May 21, 2015)

PROMISSORY NOTE SETTLEMENT AGREEMENT (Filed With SEC on March 31, 2015)

SERVICES AGREEMENT (Filed With SEC on March 31, 2015)

CONSULTING AGREEMENT (Filed With SEC on March 31, 2015)

Contract for the Compounding of Pharmaceutical Products, dated December 8, 2014 (Filed With SEC on December 15, 2014)

Exhibit 10.1 Clinical Trial Agreement dated October 20, 2014 between TNI BioTech International Ltd. and American Hospital and Resorts (Filed With SEC on October 30, 2014)

Exhibit 1.1 Supplementary Agreement on New Drug Methionine Enkephalin Cooperation, dated August 6, 2014, between TNI BioTech, Inc. and Hubei Qianjiang Pharmaceutical Co., Ltd (Filed With SEC on August 13, 2014)

Exhibit 1.2 Assignment by Professor Fengping Shan Ph.D. to the Company, executed August 6, 2014 (Filed With SEC on August 13, 2014)

Exhibit 1.1 Distribution Agreement, dated June 11, 2014, between Airmed Biopharma Limited and PanAm Global Logistics, Inc (Filed With SEC on June 25, 2014)

Promissory note to Robert J. Dailey, issued February 6, 2014 for $200,000 (Filed With SEC on May 15, 2014)

Promissory note to Robert J. Dailey, issued March 7, 2014 for $200,000 (Filed With SEC on May 15, 2014)

Promissory note to Robert J. Dailey, issued March 28, 2014 for $200,000 (Filed With SEC on May 15, 2014)

Employment Agreement between Cytocom, Inc. and Dr. Graham Burton dated April 1, 2014 (Filed With SEC on May 15, 2014)

Employment Agreement between Cytocom, Inc. and Gary Gemignani dated April 1, 2014 (Filed With SEC on May 15, 2014)

Exhibit 10.16 1 2 3 4 5 6 7 (Filed With SEC on March 31, 2014)

Exhibit 10.17 (Filed With SEC on March 31, 2014)

DISTRIBUTION AGREEMENT (Filed With SEC on March 31, 2014)

DISTRIBUTION AGREEMENT (Filed With SEC on October 2, 2013)

Category

Industry

Companies

Contracts

Immune Therapeutics, Inc. Contracts & Agreements